Ondrej Benek

Hradec Kralove, KR 50005, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Development of Novel 17β-HSD10 Inhibitors and Their Evaluation in an In Vitro Model of Alzheimer's Disease.

Development of Novel 17β-HSD10 Inhibitors and Their Evaluation in an In Vitro Model of Alzheimer's Disease.

Journal: ACS medicinal chemistry letters

Published: March 09, 2026

New insights into the 17β-hydroxysteroid dehydrogenase type 10 and amyloid-β 42 derived cytotoxicity relevant to Alzheimer's disease.

New insights into the 17β-hydroxysteroid dehydrogenase type 10 and amyloid-β 42 derived cytotoxicity relevant to Alzheimer's disease.

Journal: Alzheimer's research & therapy

Published: April 22, 2025

N-4-aminobenzyl-N'-(2-(2-phenylpyrrolidin)-2-oxoethyl)urea-based inhibitors of cyclophilin D - Preparation of distinct stereoisomers and comparative analysis of their in vitro bioactivity.

N-4-aminobenzyl-N'-(2-(2-phenylpyrrolidin)-2-oxoethyl)urea-based inhibitors of cyclophilin D - Preparation of distinct stereoisomers and comparative analysis of their in vitro bioactivity.

Journal: Bioorganic chemistry

Published: March 19, 2025

Immobilized animal liver microsomes: A versatile tool for efficient ester hydrolysis in chemo-enzymatic synthesis.

Immobilized animal liver microsomes: A versatile tool for efficient ester hydrolysis in chemo-enzymatic synthesis.

Journal: Methods (San Diego, Calif.)

Published: February 12, 2025

Human Cyclophilins-An Emerging Class of Drug Targets.

Human Cyclophilins-An Emerging Class of Drug Targets.

Journal: Medicinal research reviews

Published: October 01, 2024

Neuroprotective Effect of 2-(Benzyloxy)arylureas Is Not Related to CypD Inhibition nor Suppression of mPTP Opening.

Neuroprotective Effect of 2-(Benzyloxy)arylureas Is Not Related to CypD Inhibition nor Suppression of mPTP Opening.

Journal: ACS medicinal chemistry letters

Published: July 20, 2024

Exploring the interaction of N-(benzothiazol-2-yl)pyrrolamide DNA gyrase inhibitors with the GyrB ATP-binding site lipophilic floor: A medicinal chemistry and QTAIM study.

Exploring the interaction of N-(benzothiazol-2-yl)pyrrolamide DNA gyrase inhibitors with the GyrB ATP-binding site lipophilic floor: A medicinal chemistry and QTAIM study.

Journal: Bioorganic & medicinal chemistry

Published: May 08, 2024

Nanomolar Benzothiazole-Based Inhibitors of 17β-HSD10 with Cellular Bioactivity.

Nanomolar Benzothiazole-Based Inhibitors of 17β-HSD10 with Cellular Bioactivity.

Journal: ACS medicinal chemistry letters

Published: August 11, 2023

Physiologically relevant fluorescent assay for identification of 17β-hydroxysteroid dehydrogenase type 10 inhibitors.

Physiologically relevant fluorescent assay for identification of 17β-hydroxysteroid dehydrogenase type 10 inhibitors.

Journal: Journal of neurochemistry

Published: March 07, 2023

Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation.

Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation.

Journal: European journal of medicinal chemistry

Published: December 23, 2022

Small-molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria-related diseases.

Small-molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria-related diseases.

Journal: Medicinal research reviews

Published: October 07, 2021

New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.

New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.

Journal: European journal of medicinal chemistry

Published: October 06, 2020

Showing 1-12 of 32

Last Updated: 09/26/2026